Last reviewed · How we verify

AT7519M — Competitive Intelligence Brief

AT7519M (AT7519M) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK2 inhibitor. Area: Oncology.

phase 2 JAK2 inhibitor JAK2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AT7519M (AT7519M) — Astex Pharmaceuticals, Inc.. AT7519M is a potent inhibitor of the JAK2 protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AT7519M TARGET AT7519M Astex Pharmaceuticals, Inc. phase 2 JAK2 inhibitor JAK2
Leqselvi DEURUXOLITINIB Sun Pharm Inds Inc marketed JAK1, JAK2, TYK2 2024-01-01
Vonjo PACRITINIB Sobi marketed Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 2022-01-01
Inrebic FEDRATINIB HYDROCHLORIDE Bristol-Myers Squibb marketed JAK2, FLT3 2019-01-01
Olumiant baricitinib Eli Lilly marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 2018-01-01
Corectim DELGOCITINIB Japan Tobacco marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2
Letybo® Letybo® Yuvell marketed FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor FLT3, JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK2 inhibitor class)

  1. Astex Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AT7519M — Competitive Intelligence Brief. https://druglandscape.com/ci/at7519m. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: